Law360, New York (March 20, 2012, 7:46 PM EDT) -- On March 20, 2012, the U.S. Supreme Court unanimously reversed the Court of Appeals for the Federal Circuit holding that Prometheus's patents — claiming methods for determining the optimal dosages of thiopurine drugs to treat certain diseases — were directed to nonstatutory subject matter pursuant to 35 U.S.C. § 101 and therefore not patent-eligible. Mayo Collaborative Servs. v. Prometheus Labs. Inc., 566 U.S. ___ (2012).
The Supreme Court's opinion is its second recent major decision in the field of patent-eligible subject matter of method
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.